Lymphocyte Adhesion Coreceptors and their Roles in HIV-1 Replication

1996 ◽  
pp. 79-91
Author(s):  
Jeffrey A. Ledbetter
Keyword(s):  
Blood ◽  
2009 ◽  
Vol 114 (15) ◽  
pp. 3335-3342 ◽  
Author(s):  
Chiara Urbinati ◽  
Stefania Nicoli ◽  
Mauro Giacca ◽  
Guido David ◽  
Simona Fiorentini ◽  
...  

Abstract The HIV-1 transactivating factor Tat accumulates on the surface of endothelium by interacting with heparan sulfate proteoglycans (HSPGs). Tat also interacts with B-lymphoid Namalwa cells but only when these overexpress HSPGs after syndecan-1 cDNA transfection (SYN-NCs). Accordingly, SYN-NCs, but not mock-transfected cells, adhere to endothelial cells (ECs) when Tat is bound to the surface of either one of the 2 cell types or when SYN-NCs are transfected with a Tat cDNA. Moreover, endogenously produced Tat bound to cell-surface HSPGs mediates cell adhesion of HIV+ ACH-2 lymphocytes to the endothelium. This heterotypic lymphocyte-EC interaction is prevented by HSPG antagonist or heparinase treatment, but not by integrin antagonists and requires the homodimerization of Tat protein. Tat tethered to the surface of SYN-NCs or of peripheral blood monocytes from healthy donors promotes their transendothelial migration in vitro in response to CXCL12 or CCL5, respectively, and SYN-NC extravasation in vivo in a zebrafish embryo model of inflammation. In conclusion, Tat homodimers bind simultaneously to HSPGs expressed on lymphoid and EC surfaces, leading to HSPG/Tat-Tat/HSPG quaternary complexes that physically link HSPG-bearing lymphoid cells to the endothelium, promoting their extravasation. These data provide new insights about how lymphoid cells extravasate during HIV infection.


Molecules ◽  
2021 ◽  
Vol 26 (24) ◽  
pp. 7488
Author(s):  
Chiara Urbinati ◽  
Maria Milanesi ◽  
Nicola Lauro ◽  
Cinzia Bertelli ◽  
Guido David ◽  
...  

HIV-1 transactivating factor Tat is released by infected cells. Extracellular Tat homodimerizes and engages several receptors, including integrins, vascular endothelial growth factor receptor 2 (VEGFR2) and heparan sulfate proteoglycan (HSPG) syndecan-1 expressed on various cells. By means of experimental cell models recapitulating the processes of lymphocyte trans-endothelial migration, here, we demonstrate that upon association with syndecan-1 expressed on lymphocytes, Tat triggers simultaneously the in cis activation of lymphocytes themselves and the in trans activation of endothelial cells (ECs). This “two-way” activation eventually induces lymphocyte adhesion and spreading onto the substrate and vascular endothelial (VE)-cadherin reorganization at the EC junctions, with consequent endothelial permeabilization, leading to an increased extravasation of Tat-presenting lymphocytes. By means of a panel of biochemical activation assays and specific synthetic inhibitors, we demonstrate that during the above-mentioned processes, syndecan-1, integrins, FAK, src and ERK1/2 engagement and activation are needed in the lymphocytes, while VEGFR2, integrin, src and ERK1/2 are needed in the endothelium. In conclusion, the Tat/syndecan-1 complex plays a central role in orchestrating the setup of the various in cis and in trans multimeric complexes at the EC/lymphocyte interface. Thus, by means of computational molecular modelling, docking and dynamics, we also provide a characterization at an atomic level of the binding modes of the Tat/heparin interaction, with heparin herein used as a structural analogue of the heparan sulfate chains of syndecan-1.


Author(s):  
James K. Koehler ◽  
Steven G. Reed ◽  
Joao S. Silva

As part of a larger study involving the co-infection of human monocyte cultures with HIV and protozoan parasites, electron microscopic observations were made on the course of HIV replication and infection in these cells. Although several ultrastructural studies of the cytopathology associated with HIV infection have appeared, few studies have shown the details of virus production in “normal,” human monocytes/macrophages, one of the natural targets of the virus, and suspected of being a locus of quiescent virus during its long latent period. In this report, we detail some of the interactions of developing virons with the membranes and organelles of the monocyte host.Peripheral blood monocytes were prepared from buffy coats (Portland Red Cross) by Percoll gradient centrifugation, followed by adherence to cover slips. 90-95% pure monocytes were cultured in RPMI with 5% non-activated human AB serum for four days and infected with 100 TCID50/ml of HIV-1 for four hours, washed and incubated in fresh medium for 14 days.


1997 ◽  
Vol 23 (3) ◽  
pp. 83-92 ◽  
Author(s):  
D. Seilhean ◽  
A. Dzia-Lepfoundzou ◽  
V. Sazdovitch ◽  
B. Cannella ◽  
C. S. Raine ◽  
...  

2000 ◽  
Vol 14 (2) ◽  
pp. 50-55
Author(s):  
FORTHEPEDIATRICPULMONARYANDCA ◽  
H COHEN ◽  
X CHEN ◽  
S SUNKLE ◽  
L DAVIS ◽  
...  

2020 ◽  
Author(s):  
Juan Ambrosioni ◽  
Elisa Petit ◽  
Geoffroy Liegeon ◽  
Montserrat Laguno ◽  
José M Miró
Keyword(s):  

2014 ◽  
Vol 71 (8) ◽  
pp. 451-460
Author(s):  
Jörg Schüpbach ◽  
Christoph Berger ◽  
Jürg Böni ◽  
Roberto F. Speck
Keyword(s):  
Hiv Test ◽  

„HIV-positiv“ ist auch heute noch eine belastende Diagnose. Falsch positive wie falsch negative HIV-Test-Resultate herauszugeben, muss unbedingt vermieden werden. Das Bundesamt für Gesundheit (BAG) hat ein HIV-Testkonzept entworfen, das dieser Anforderung gerecht wird und darüber hinaus das Virus im betroffenen Patienten detailliert für eine optimale medizinische Betreuung charakterisiert. Das Testkonzept fordert hierzu die Beantwortung der folgenden vier Fragen: 1. Ist die getestete Person tatsächlich HIV-infiziert? 2. Handelt es sich um eine Infektion mit HIV-1 oder HIV-2, und im Falle von HIV-1, um welche Virusgruppe, M oder O? Sind Resistenzen gegenüber den antiretroviralen Medikamenten vorhanden? 3. Wie hoch ist die Viruslast? 4. Wie hoch ist der Anteil frischer HIV-Infektionen an den neu gemeldeten Fällen? In diesem Artikel werden wir das Testkonzept besprechen. Abschliessend werden wir in einer kurzen Übersicht darlegen, was der Arzt bei einer Erst- und Folgekonsultation bei einem HIV-infizierten Patienten abklären sollte.


Sign in / Sign up

Export Citation Format

Share Document